Previous 10 | Next 10 |
home / stock / cdmop / cdmop news
TUSTIN, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pha...
Avid Bioservices, Inc. (CDMO) Q4 2021 Earnings Conference Call June 29, 2021 16:30 ET Company Participants Tim Brons - Investor Relations, Vida Strategic Partners Nick Green - President & Chief Executive Officer Dan Hart - Chief Financial Officer Conference Call Participants Thomas Kellih...
-- Recorded Fourth Quarter Revenue of $27.6 Million and Annual Revenue of $95.9 Million -- -- Achieved Four Consecutive Quarters of Operational Profitability During Fiscal 2021 -- -- Signed Approximately $148 Million in New Business Orders and Achieved a Year-End Backlog o...
TUSTIN, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pha...
TUSTIN, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to bi...
Studies suggest that index rebalancing anomalies generate excess risk-adjusted returns caused by stock index funds and institutional investors that benchmark the indexes. In my prior three-year study from 2017, abnormal gains were identified from the annual June rebalancing and some p...
TUSTIN, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (the “company”), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing s...
TUSTIN, Calif., March 17, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biote...
TUSTIN, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (the “company”), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and m...
Avid Bioservices, Inc. (CDMO) Q3 2021 Earnings Conference Call March 8, 2021 16:30 ET Company Participants Tim Brons - Investor Relations, Vida Strategic Partners Nick Green - President & Chief Executive Officer Dan Hart - Chief Financial Officer Timothy Compton - Chief Commercial Officer...
News, Short Squeeze, Breakout and More Instantly...
Avid Bioservices Inc. 10.50% Series E Convertible Preferred Stock Company Name:
CDMOP Stock Symbol:
NASDAQ Market:
Avid Bioservices Inc. 10.50% Series E Convertible Preferred Stock Website:
-- Recorded Fourth Quarter Revenue of $43.0 Million – Highest in Company History -- -- Signed $30 Million in Net New Business Resulting in Backlog of $193 Million -- -- New Mammalian and Cell and Gene Therapy Facilities Fully Operational and in Service; Capital Expenditur...
TUSTIN, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announc...
TUSTIN, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and phar...